Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Rhea-AI Summary
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash.
The deal would add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, with closing expected in the first half of Fiscal 2027, subject to regulatory approvals.
AI-generated analysis. Not financial advice.
Positive
- Upfront cash acquisition of SPR Therapeutics for approximately $650 million
- Adds FDA-cleared SPRINT 60-day PNS System to Medtronic pain portfolio
- Expands minimally invasive, non-opioid chronic pain options earlier in care continuum
- Retrospective review of 6,100+ patients showed over 71% with significant pain relief and/or quality-of-life improvement
- Strengthens Medtronic’s neuromodulation offering in a growing PNS segment
Negative
- Transaction requires customary closing conditions and regulatory approvals before completion
- Medtronic will deploy approximately $650 million in cash for the acquisition
News Market Reaction – MDT
On the day this news was published, MDT declined 1.32%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MDT was up 1.63% while key peers were mixed: SYK +1.38%, BSX +0.60%, ZBH +0.97%, EW -0.16%, PHG 0.00%. With no peers in the momentum scanner and no same-day peer headlines, the move appears more company-specific than sector-driven.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Acquisition completion | Positive | -1.4% | Closed CathWorks acquisition valued at $585M adding AI-driven FFRangio system. |
| Mar 10 | Acquisition agreement | Positive | -1.6% | Agreed to acquire Scientia Vascular for $550M to expand neurovascular tools. |
| Feb 03 | Acquisition intent | Positive | +0.5% | Announced intent to acquire CathWorks, expanding interventional cardiology portfolio. |
| Aug 27 | Asset divestiture | Neutral | -0.6% | PaceMate acquired Medtronic’s Paceart Optima system, expanding its cardiac data reach. |
Recent acquisition headlines for MDT have produced modest average moves of about -0.78%, often skewing slightly negative even on strategically positive news.
Over the last two years, Medtronic has used M&A both to add technology and to streamline its portfolio. Prior deals include intent and completion of the CathWorks acquisition ($585M) and the agreement to acquire Scientia Vascular for $550M, plus a divestiture of the Paceart Optima system to PaceMate. Those transactions typically led to small share price moves around -0.78% on average, suggesting acquisition news has historically been absorbed without large re-ratings.
Historical Comparison
In the past 18 months, MDT logged 4 acquisition-related headlines with an average move of -0.78%. Today’s positive reaction contrasts with that slightly negative history.
Acquisition activity shows a pattern of targeted portfolio shaping: adding cardiovascular and neurovascular technologies while divesting non-core assets like Paceart Optima.
Regulatory & Risk Context
An effective Form S-3ASR shelf filed on 2026-03-09 allows Medtronic and affiliates to issue debt securities from time to time, fully and unconditionally guaranteed on a joint and several basis by designated group entities. Specific amounts and terms would be set in future prospectus supplements. No usage has been recorded to date.
Market Pulse Summary
This announcement adds a temporary peripheral nerve stimulation platform to Medtronic’s neuromodulation portfolio via a $650 million cash deal. SPR’s SPRINT PNS System has been used in more than 6,100 patients, with over 71% showing meaningful benefit after a 60‑day therapy course. Historically, Medtronic’s acquisition news has produced modest share moves around -0.78%. Investors may track closing progress in 1H FY27 and subsequent updates on neuromodulation growth and capital deployment.
Key Terms
peripheral nerve stimulation medical
fda-cleared regulatory
retrospective review technical
AI-generated analysis. Not financial advice.
Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferers
GALWAY,
Drawing on Medtronic's 50 years of neuromodulation leadership, including the industry's broadest pain therapy portfolio1, this planned acquisition will increase Medtronic's ability to reach and support more people with complementary, minimally invasive pain relief options earlier in their care continuum.
Chronic pain affects nearly 50 million
"Our purpose first and foremost is to serve patients," said Domenico De Paolis, Interim President Neuromodulation, part of the Medtronic Neuroscience Portfolio. "That is why we continue to thoughtfully expand our pain intervention therapies. The addition of temporary peripheral nerve stimulation helps broaden access to neuromodulation and supports patients across more stages of the chronic pain journey with a minimally invasive therapy."
The PNS segment continues to grow, driven by increasing clinical evidence, expanding reimbursement, and demand for non-opioid, less-invasive pain therapies. To date, the largest retrospective review of real-world PNS data, which includes more than 6,100 patients, was conducted using the SPRINT PNS System and showed over 71 percent of study participants demonstrated significant pain relief and/or improvement in quality of life following 60-day percutaneous PNS treatment3.
"Guided by our credo to advancing meaningful, patient-centered innovation in pain medicine, our agreement with Medtronic marks a pivotal step forward," said Maria E. Bennett, President and Chief Executive Officer of SPR Therapeutics. "Together, we will reach more patients helping them find relief earlier in their care journey to reclaim their lives and get back to what matters most."
This transaction is subject to customary closing conditions and regulatory approvals. The anticipated close date will fall within the first half of Medtronic's Fiscal Year 2027, which officially began on April 25, 2026. Until closing, Medtronic and SPR Therapeutics will continue to operate as separate and independent companies.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway,
About SPR
SPR is a medical technology company focused on advancing minimally invasive therapies for the treatment of pain. Its SPRINT® PNS System is designed to deliver short-term peripheral nerve stimulation therapy for sustained pain relief, supported by a growing body of clinical evidence and expanding reimbursement coverage. For more information on SPR Therapeutics, visit sprpainrelief.com and follow SPR on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the
Medtronic Contacts: | |
Justin Paquette | Ingrid Goldberg |
Public Relations | Investor Relations |
+1-612-271-7935 |
References
- Medtronic SCS Value Summary FY25; Lo Bianco, G., et al. (2025). Barriers to neuromodulation. J Anesth Analg Crit Care, 5(1):3.
- American Chronic Pain Association. Pain Fact Sheet. Found at https://www.acpanow.com/uploads/9/9/8/3/99838302/pain_fact_sheet.pdf
- Huntoon, E. A., et al. (2023). A retrospective review of real-world outcomes following 60-day PNS for the treatment of chronic pain. *Pain Practice*.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-intent-to-acquire-spr-therapeutics-inc-expanding-care-options-for-people-living-with-chronic-pain-302777023.html
SOURCE Medtronic plc